PhRMA submitted a pre-hearing brief to the U.S. International Trade Commission (USITC) concerning its Section 332 investigation titled “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities.” The innovative biopharmaceutical industry worked around the clock to research, develop and deploy vaccines and therapeutics to treat and prevent infections from the novel coronavirus and associated conditions – all while maintaining the supply of existing treatments and vaccines and developing new medicines for other diseases. This brief details the significant risks from the TRIPS waiver that undermine pandemic response and future preparedness.